Safinamide

Evidence Level: L5

Predicted Indications: 3

Safinamide

Pharmacist Assessment Report

Safinamide: From Parkinson Disease to Rasmussen Subacute Encephalitis

One-Sentence Summary

Safinamide was originally used to treat Parkinson disease and related parkinsonian syndromes. The TxGNN model predicts it may be effective for Rasmussen subacute encephalitis, but no clinical trials and no publications currently support this direction, so it rests on the model prediction alone.

Quick Overview

Item	Content
Original Indication	Parkinson disease (and related parkinsonian syndromes)
Predicted New Indication	Rasmussen subacute encephalitis
TxGNN Prediction Score	0.9963
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Safinamide is a reversible MAO-B inhibitor. It also blocks voltage-gated sodium channels and inhibits glutamate release. Together, these actions could plausibly relate to the excitotoxicity and seizure activity seen in Rasmussen encephalitis.

However, the original indication (Parkinson disease) is a neurodegenerative movement disorder, whereas Rasmussen encephalitis is driven mainly by T-cell-mediated autoimmune inflammation of one cerebral hemisphere. Safinamide does not address this immune mechanism. The link therefore rests on the high TxGNN score (0.9963) alone, with no supporting clinical or literature evidence.

Other predictions for this drug are weaker or similarly unsupported:

Myelitis (score 0.9946): No established mechanistic rationale for treating spinal cord inflammation.
PLA2G6-associated neurodegeneration (score 0.9922): The parkinsonian phenotype overlaps with the approved indication, so symptomatic dopaminergic support is conceivable. This is the most plausible symptomatic rationale of the three, but it remains a hypothesis and would not alter the underlying disease.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02484641	ONSTRYV	Not listed	Not listed
02484668	ONSTRYV	Not listed	Not listed

Safety Considerations

Drug Interactions: 100 interactions were identified in the DDI screening. The first 20 reviewed include one Major interaction and the rest Moderate.
- Major: Bupropion
- Moderate (sympathomimetics and appetite suppressants): Isometheptene, Diethylpropion, Phentermine
- Moderate (antidiabetic agents): Chlorpropamide, Acetohexamide, Glimepiride, Nateglinide, Repaglinide, Empagliflozin, and multiple insulin products (aspart, degludec, detemir, glargine, glulisine, human isophane, human regular, inhaled human)
- Moderate (other): Metoclopramide, Rosuvastatin

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a very high model score but no clinical trials or publications behind it (Evidence Level L5). The mechanism of safinamide does not address the autoimmune inflammation that drives Rasmussen encephalitis, so the rationale is weak.

To proceed, the following is needed:

Preclinical or mechanistic studies linking MAO-B inhibition or sodium channel/glutamate modulation to Rasmussen encephalitis
A literature and trial registry search to confirm whether any supporting evidence exists
Package insert warnings and contraindications from Health Canada, to complete the safety review
Detailed mechanism of action data
Approved indication text and dosage form details for the Canadian products
Review of the major bupropion interaction and the antidiabetic drug interactions, if any further evaluation is pursued
If a more plausible symptomatic use is of interest, consider evaluating PLA2G6-associated neurodegeneration first
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.